Drugs / Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)
Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)
also known as
DTcP
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05951725 | Aug 2023 → Apr 2025 overdue | — | CanSino Biologics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP) | “Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP)” NCT05951725 ↗ |
| Known as | DTcP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05951725 ↗ |
| Modality | Vaccine | “The (Diphtheria-tetanus-component acellular pertussis vaccine, DTcP) vaccine” NCT05951725 ↗ |